Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.54 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.53 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | ROS1 | P08922 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | FLT4 | P35916 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30460067 | 1.00 | EGFR (0.54) | EGFRMKNK2MKNK1JAK2ROS1 | |
| SCHEMBL29555980 | 0.91 | MKNK1 (0.65) | EGFRMKNK2MKNK1JAK2ROS1 | |
| SCHEMBL32671769 | 0.91 | MKNK1 (0.65) | EGFRMKNK2MKNK1JAK2ROS1 | |
| SCHEMBL14660648 | 0.91 | MKNK1 (0.65) | EGFRMKNK2MKNK1JAK2ROS1 | |
| SCHEMBL18607012 | 0.90 | EGFR (0.45) | EGFRMKNK2MKNK1JAK2ROS1 | |
| SCHEMBL30459887 | 0.90 | MKNK2 (0.49) | EGFRMKNK2MKNK1 | |
| Hydrochloric Acid SCHEMBL31218386 | 0.90 | MKNK1 (0.64) | EGFRMKNK2MKNK1JAK2ROS1 | |
| SCHEMBL17683312 | 0.89 | EGFR (0.55) | EGFRMKNK2MKNK1JAK2ROS1 | |
| SCHEMBL30459800 | 0.89 | EGFR (0.55) | EGFRMKNK2MKNK1JAK2ROS1 | |
| SCHEMBL28382476 | 0.89 | EGFR (0.56) | EGFRMKNK2MKNK1JAK2ROS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117402143-A | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-117069700-A | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-117050062-A | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-111187221-B | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-111171000-B | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-111170999-B | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2023-06-30 | — | — | CN | disclosed |
| EP-3205650-B1 | EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2021-08-04 | — | — | EP | disclosed |
| EP-3205650-B1 | EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2021-08-04 | — | — | EP | disclosed |
| CN-111187221-A | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2020-05-22 | — | — | CN | disclosed |
| CN-111171000-A | EGFR inhibitor and preparation and application thereof | 上海翰森生物医药科技有限公司 | 2020-05-19 | — | — | CN | disclosed |
| US-10259820-B2 | EGFR inhibitor, preparation method and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2019-04-16 | — | — | US | disclosed |
| US-10259820-B2 | EGFR inhibitor, preparation method and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2019-04-16 | — | — | US | disclosed |
| US-20190100528-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2019-04-04 | — | — | US | disclosed |
| US-20190100528-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2019-04-04 | — | — | US | disclosed |
| US-20170313714-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170313714-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170313714-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| EP-3205650-A1 | EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2017-08-16 | — | — | EP | disclosed |
| EP-3205650-A1 | EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016054987-A1 | EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313714-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | EGFR 1/4885MKNK2 2422/4885MKNK1 2279/4885 |
| US-20190100528-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | EGFR 1/4885MKNK2 2701/4885MKNK1 2644/4885 |
| US-10259820-B2 | EGFR inhibitor, preparation method and use thereof | EGFR, ERBB2, ERBB4 | EGFR 1/4885MKNK2 2422/4885MKNK1 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.